IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
about
The epigenetic landscape of acute myeloid leukemiaEpigenetic regulators and their impact on therapy in acute myeloid leukemiaProgress in acute myeloid leukemiaCIViC databaseDifferential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia.Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cellsPathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.Novel multiplex bead-based assay for detection of IDH1 and IDH2 mutations in myeloid malignancies.CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patientsMutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapyIntegrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemiaFrequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617FMolecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patientsProfiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysisOverexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO)Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotypeThe Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.IDH1 and IDH2 mutations in pediatric acute leukemiaIsocitrate dehydrogenase mutations in myeloid malignancies.Current findings for recurring mutations in acute myeloid leukemiaPrognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.Impaired TCA cycle flux in mitochondria in skeletal muscle from type 2 diabetic subjects: marker or maker of the diabetic phenotype?Molecular diagnosis of leukemia.Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.Molecular markers in acute myeloid leukaemia.Acute myeloid leukemia with normal cytogenetics.Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.
P2860
Q21284742-72D5D068-A0CA-4D19-9864-131D65A8ADE4Q26765402-90DF4440-CA4C-427B-9570-46C17E220E68Q27024006-78E6A116-1922-43BC-AD61-ABAE7CD6BF2AQ27612411-3C13ABEC-5560-465A-B04D-0659D639B5D4Q27851680-ABAB7712-8A48-4604-A07E-5A34E84A41B7Q27851805-B618A64E-226E-4F7C-9660-E9E5D049A61DQ27851909-55590F7B-C2BD-4727-B62B-EFC9BE357654Q33699608-AB2BB5B0-7D07-4CFD-8972-8E3DBAC858A6Q34224704-B1EB6180-7CAA-47D8-AFA3-6FC42F8C4B2AQ34347935-DDF11263-E3A7-4292-A19D-8D90CC08B4D4Q34647637-48453B3A-62C5-4147-9725-7D2654561560Q34667249-962036DF-0D23-4993-9D2E-BB77C85B7994Q34876800-D1E22F39-EA0F-4662-8968-5872B66506BDQ35010433-6CBE2568-2B95-4B2A-AD5D-3BB83500C6C3Q35018518-C35EB733-0B04-40FF-92CC-1DE6F1C58C9CQ35078037-4B5A1CCD-948F-40A1-BA3C-E2A8C325991DQ35132953-241179DC-DB4F-4A5F-BC59-4EA8584BB778Q35562821-6F221101-1C2C-4A06-AE8F-5CCAC20A163EQ35705307-E66EE559-7DDD-49C7-9D10-FD1E929D45F4Q35835653-0D52992A-607F-468C-B9F4-D5710F88CC3AQ35873466-43126C18-3C81-44F2-9D7A-D8547DEB25F8Q36322776-DA5839E2-28C4-4502-9064-E0524E49B80DQ36439908-BE549AA3-7642-4828-AAFE-A868BE2199DAQ36500377-1A820C48-354F-466A-8199-13BDFC6C451AQ36500411-EFAF8712-714D-4821-B361-A59B446BA8FDQ36849666-A5682356-9B22-4495-BF36-C5817A5CAA46Q36887700-3808BCA1-3B8A-472F-AEAE-CD81D79185AFQ37432049-5EB5345B-B06D-408F-B422-6497F42FCB5BQ37443338-DAC39DDF-F3AB-48B7-AFC0-C4B36941A056Q37444122-F5968401-F487-4CEB-B4D1-8ED517AC5C71Q37625630-9189CD45-0563-4C00-86E8-95CA8F510064Q37932085-7832E43F-0A53-4376-A449-D417CFFB5C4EQ37954583-DA96774F-0769-4C47-80D9-A6390B915065Q37990035-5E344066-2D3A-4DD3-A823-000DC8FB5858Q38018998-CB0995C7-2EC0-4A4A-B7A4-22E073998F98Q38022075-D93ACDA9-4CAF-42BB-A993-0ADBB43FE3BAQ38026007-C064BD53-E990-4CFD-A180-1FEF1FD432ABQ38027047-D79B279E-C53E-4BC8-BFF5-0C03525418DBQ38044773-47365C1A-49AB-4B4D-8374-0C0A3C476EB0Q38121089-72C31423-38AD-4B2B-A234-3E9F8F4196CB
P2860
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
IDH1 mutations are detected in ...... ars and unmutated NPM1 status.
@ast
IDH1 mutations are detected in ...... ars and unmutated NPM1 status.
@en
IDH1 mutations are detected in ...... ars and unmutated NPM1 status.
@nl
type
label
IDH1 mutations are detected in ...... ars and unmutated NPM1 status.
@ast
IDH1 mutations are detected in ...... ars and unmutated NPM1 status.
@en
IDH1 mutations are detected in ...... ars and unmutated NPM1 status.
@nl
prefLabel
IDH1 mutations are detected in ...... ars and unmutated NPM1 status.
@ast
IDH1 mutations are detected in ...... ars and unmutated NPM1 status.
@en
IDH1 mutations are detected in ...... ars and unmutated NPM1 status.
@nl
P50
P3181
P1433
P1476
IDH1 mutations are detected in ...... ars and unmutated NPM1 status.
@en
P2093
Madlen Ulke
Wolfgang Kern
P304
P3181
P356
10.1182/BLOOD-2010-02-267955
P407
P577
2010-12-16T00:00:00Z